USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: MOLECULES FOR HEALTH, INC.
City: RICHMOND
State: VA
Zip+4: 23219 1534
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $788,195.00 9
SBIR Phase II $1,249,676.00 2

Award List:

THIS PROPOSAL IS FOR EXTENDING THE EVALUATION OF RIBONUCLEOTIDE REDUCTASE INHIBITORS AS ANTITUMOR AGENTS.

Award Year / Program / Phase: 1983 / SBIR / Phase I
Agency: HHS
Principal Investigator: Howard l. elford , PRINCIPAL INVESTIGATOR
Award Amount: $55,976.00
Abstract:
This proposal is for extending the evaluation of ribonucleotide reductase inhibitors as antitumor agents. vicinical polyhydroxy and polyamino benzoic acid derivatives, especially vf147, i.e., 3.4- dihydroxybenzohydroxamic acid, have shown good activity against l1210 tumor model and against some of… More

POLYHYDROXYPHENYL DERIVATIVES DESIGNED FOR ANTITUMOR ACTIVITY

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bart van't riet phd
Award Amount: $50,000.00
Abstract:
The reductive conversion of ribonucleotides to deoxyribonucleotides, catalyzed by ribonucleotide reductase,is a crucial and rate-limiting reaction in the dna biosynthetic pathway. this reaction, therefore, represents a logical target for cancer chemotherapy. in response to the need for an effective… More

POLYHYDROXYPHENYL-CONJUGATES FOR ANTITUMOR ACTIVITY

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $49,962.00
Abstract:
The reductive conversion of ribonucleotides to deoxyribonucleotides, catalyzed by ribonucleotide reductase,is a crucial and rate-limiting reaction in the dna biosynthetic pathway, and represents a logical target for cancer chemotherapy. in response to this need, a series of ribonucleotide reductase… More

NEW DRUGS TO PREVENT REPERFUSION ISCHEMIA INJURY

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Howard Elford
Award Amount: $49,000.00

POTENTIAL NEW TOPICAL ANTI-PSORIASIS AGENTS

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elford, Howard L , Principal Investigator
Award Amount: $49,998.00
Abstract:
Psoriasis affects approximately 2 percent of the u. s. population and most present treatments are either potentially harmful or entail difficult and/or unpleasant procedures. therefore new agents are eagerly sought. the goal of this project is to develop a topical antipsoriatic agent that has… More

NEW DRUGS TO PREVENT REPERFUSION ISCHEMIA INJURY

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: Howard Elford
Award Amount: $499,963.00
Abstract:
This research is based on the thesis that oxygen-free radicals contribute in a significant way to the deleterious aspect of reperfusion after a tissue or organ is deprived ofoxygen and flow is re-initiated. the objective of this research is to determine the potential of a new series of compounds to… More

Ribonucleotide Reductase Inhibitors for AIDS Therapy

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Howard Elford
Award Amount: $99,794.00
Abstract:
We will develop a series of Ribonucleotide reductase inhibitors for the treatment of retrovirus (AIRibonucleotide reductase catalyzes the reductive conversion of ribonucleotides to deoxyribonucleotidapproach is the premise that the quantity of deoxynucleotides can be made deficient for the… More

Ribonucleotide Reductase Inhibitors for AIDS Therapy

Award Year / Program / Phase: 1998 / SBIR / Phase II
Agency: HHS
Principal Investigator: Howard Elford
Award Amount: $749,713.00
Abstract:
We will develop a series of Ribonucleotide reductase inhibitors for the treatment of retrovirus (AIRibonucleotide reductase catalyzes the reductive conversion of ribonucleotides to deoxyribonucleotidapproach is the premise that the quantity of deoxynucleotides can be made deficient for the… More

Novel Cancer Drugs to Prevent Doxorubicin Toxicity

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Howard L. Elford
Award Amount: $107,767.00
Abstract:
DESCRIPTION (provided by applicant): Doxorubicin, an anthracycline drug, is effective against numerous solid and hematological cancers, but cardiotoxicity limits its usefulness. The specific goal of this research project is to determine the potential of two MFH anticancer… More

Radical Scavengers for Brain Ischemia Reperfusion injury

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Howard L. Elford
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The goal of this proposal is to determine the potential of two MFH free radical scavenging compounds, Didox and Imidate, to protect brain tissue from stroke injury due to the deleterious effects of ischemia and reperfusion. Free radical generation is strongly… More

Ribonucleotide Reductase Inhibitors for Restenosis

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $225,698.00
Abstract:
DESCRIPTION (provided by applicant): Coronary artery disease is a major health problem and the leading cause of premature death in the US. Percutaneous coronary intervention with stenting is the primary treatment strategy for many patients with occlusive v ascular pathology; however it has been… More